LUPRON DEPOT Drug Patent Profile

When do Lupron Depot patents expire, and when can generic versions of Lupron Depot launch?

Lupron Depot is a drug marketed by Abbvie Endocrine Inc and is included in five NDAs. There are two patents protecting this drug.

This drug has thirty-five patent family members in twenty-eight countries.

The generic ingredient in LUPRON DEPOT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lupron Depot

A generic version of LUPRON DEPOT was approved as leuprolide acetate by SANDOZ on August 4^th, 1998.

Summary for LUPRON DEPOT

International Patents:	35
US Patents:	2
Applicants:	1
NDAs:	5
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	136
Drug Prices:	Drug price information for LUPRON DEPOT
What excipients (inactive ingredients) are in LUPRON DEPOT?	LUPRON DEPOT excipients list
DailyMed Link:	LUPRON DEPOT at DailyMed

See drug prices for LUPRON DEPOT

Recent Clinical Trials for LUPRON DEPOT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Zenith Epigenetics	PHASE2
National Cancer Institute (NCI)	PHASE2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	PHASE2

See all LUPRON DEPOT clinical trials

US Patents and Regulatory Information for LUPRON DEPOT

LUPRON DEPOT is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020011-001	Oct 22, 1990		DISCN	Yes	No
Abbvie Endocrine Inc	LUPRON DEPOT-PED KIT	leuprolide acetate	POWDER;INTRAMUSCULAR	020263-009	Apr 14, 2023		RX	Yes	Yes
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020517-003	Jun 17, 2011		RX	Yes	Yes			Y

Expired US Patents for LUPRON DEPOT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020708-001	Mar 7, 1997
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020708-001	Mar 7, 1997
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	019732-001	Jan 26, 1989

International Patents for LUPRON DEPOT

See the table below for patents covering LUPRON DEPOT around the world.

Country	Patent Number	Title	Estimated Expiration
Bulgaria	61520
Taiwan	200833376
Japan	5258844

Market Dynamics and Financial Trajectory for LUPRON DEPOT

Last updated: December 31, 2025

Executive Summary

LUPRON DEPOT (leuprolide acetate microspheres) is an extended-release gonadotropin-releasing hormone (GnRH) agonist primarily used for conditions such as prostate cancer, endometriosis, and premenopausal breast cancer. With a high degree of specificity within the hormonal therapy space, LUPRON DEPOT commands significant market share due to its efficacy, safety profile, and convenience of administration. The drug's financial trajectory forecasts steady growth driven by rising prevalence of hormone-dependent cancers, expanding indications, and geographic expansion, particularly in emerging markets. However, competitive pressures, patent expiration risks, and evolving biosimilar landscapes pose challenges.

---

Market Overview: LUPRON DEPOT and Its Therapeutic Context

Aspect	Details
Active Ingredient	Leuprolide acetate
Delivery Form	Microspheres for intramuscular injection
Dosing Schedule	Monthly, quarterly, or semi-annual formulations
Approved Indications	Prostate cancer, endometriosis, uterine fibroids, precocious puberty, breast cancer
Market Leader	Record revenues (>USD 1.2 billion in 2022), maintained by AbbVie (formerly Takeda)

Competitive Landscape

Competitors	Key Drugs	Market Share	Notes
AbbVie/Lupin (LUPRON DEPOT)	LUPRON DEPOT	~50%	Leader in North America and Europe
Pfizer	Zevalin, Degarelix	Niche roles	Less directly competitive in depot formulations
Firmagon (Fremaneztide)	Ferring Pharmaceuticals	Emerging	Subcutaneous depot, alternative hormone therapy
Biosimilar entrants	Upcoming biosimilars, e.g., Viadur	Pending	Potential market share erosion upon approval

Market Size and Growth Dynamics

The global market for gonadotropin-releasing hormone (GnRH) agonists, including LUPRON DEPOT, is projected to grow at a CAGR of around 4.2% between 2022 and 2027, reaching an estimated USD 2.9 billion by 2027 [1]. Key growth drivers include:

• Increasing incidence rates of prostate cancer (worldwide annual incidence >1.4 million)
• Rising prevalence of endometriosis (estimated 10% of women of reproductive age)
• Expanding indications such as hormone-sensitive breast cancers in premenopausal women
• Improved access in emerging markets driven by healthcare infrastructure development

---

Regulatory and Patent Landscape

Period	Milestone	Impact
Patent Expiry (US)	Approximately 2027-2030 for original formulations	Potential biosimilar entry; price competition
Regulatory Approvals	Foreign markets (China, India, Brazil)	Broadening global footprint
Recent Approvals	Subcutaneous agents, combination therapies	Diversification of portfolio

Patent protections currently shield LUPRON DEPOT through 2027-2030, after which biosimilars are expected to penetrate, pressuring pricing and margins.

---

Financial Trajectory and Revenue Projections

Year	Estimated Global Revenue	Growth Rate	Assumptions & Drivers
2022	USD 1.2 billion	--	Peak revenues, stable market position
2023	USD 1.3 billion	+8.3%	Slight market expansion, new indications
2024	USD 1.4 billion	+7.7%	Emerging markets, clinical trial boosts
2025	USD 1.6 billion	+14.3%	Potential biosimilar competition mitigation
2026	USD 1.8 billion	+12.5%	Continued market penetration

Key Revenue Drivers

• Prevalence-Driven Demand: Increasing patient pool globally.
• Line Extensions & New Indications: Expanded use in oncology and juvenile indications.
• Geographic Expansion: Penetration into Asia-Pacific and Latin America markets.
• Pricing Strategies: Premium pricing in developed markets until biosimilars emerge.

---

Market Challenges and Risks

Challenge	Details	Mitigation Strategies
Patent Expiration	Biosimilar competition post-2027	Innovation, life-cycle management, formulation improvements
Market Saturation	Limited incremental growth in mature markets	Focus on emerging markets, new indications
Pricing Pressures	Governmental and payer negotiations	Value-based pricing, demonstrating cost-effectiveness
Regulatory Risks	Delays or denials for new indications or formulations	Strategically targeted clinical development

---

Comparative Analysis: LUPRON DEPOT vs. Alternatives

Parameter	LUPRON DEPOT	Degarelix	Firmagon	Biosimilar GnRH Agonists
Administration Frequency	Monthly, quarterly, semi-annual	Monthly	Monthly	Variable, often monthly
Route	Intramuscular injection	Subcutaneous	Subcutaneous	Subcutaneous or intramuscular
Onset of Action	Rapid, within days	Similar to LUPRON DEPOT	Similar	Comparable
Side Effect Profile	Hot flashes, osteoporosis, injection site reactions	Similar	Similar	Similar
Market Penetration	High in developed regions	Growing in certain niches	Niche	Expected post-2027

---

Deep Dive: Future Opportunities & Growth Areas

• Combination Therapies: Combining LUPRON DEPOT with other agents such as androgen receptor inhibitors for advanced prostate cancer.

• New Indications: Investigating expanding the therapy for breast cancer, endometrial hyperplasia, and juvenile customers.

• Drug Delivery Innovation: Developing less invasive or longer-acting formulations to extend dosing intervals further.

• Digital & Data Analytics: Leveraging health data for targeted patient management, improving adherence, and outcomes.

---

Key Market Trends and Policy Landscape

Trend	Implication	Policies & Initiatives
Aging Populations	Increased demand in hormone-dependent cancers	Healthcare reforms prioritizing cancer care
Biosimilar Entry	Cost containment pressures	Patent laws adapted to biosimilar proliferation
Global Health Initiatives	Improving access in LMICs	Gavi, WHO programs for essential medicines

---

Key Takeaways

• Growth Trajectory: LUPRON DEPOT will maintain robust revenue growth through expanding indications, geographic reach, and aging populations.
• Patent and Biosimilar Risks: Entry of biosimilars post-2027 is a critical risk factor that could pressure profit margins.
• Market Expansion: Emerging markets present a significant upside for volume growth due to increasing healthcare infrastructure and disease awareness.
• Innovation Focus: Differentiation via formulation improvements, combination therapies, and digital health integration can sustain competitive advantage.
• Regulatory Environment: Navigating complex approval processes globally remains vital for maintaining market share and expanding indications.

---

FAQs

1. What are the primary drivers of LUPRON DEPOT's market growth?

Increasing global prevalence of prostate cancer and endometriosis, expanded indications, favorable reimbursement policies, and geographic expansion are primary growth drivers.

2. When are biosimilars expected to impact LUPRON DEPOT's revenues significantly?

Biosimilars are projected to enter markets around 2027-2030, with potential to erode over USD 200 million in annual revenue unless differentiated strategies are implemented.

3. How does LUPRON DEPOT compare clinically to its competitors?

It offers a convenient intramuscular depot with proven efficacy; however, subcutaneous alternatives like Firmagon provide similar benefits with potentially fewer injections, influencing clinician choice.

4. What are emerging indications that might influence future sales?

Research into combining LUPRON DEPOT with other hormonal agents for advanced cancers and exploring juvenile indications offers growth possibilities.

5. What regulatory challenges are anticipated for LUPRON DEPOT?

Potential delays in approval for new formulations or indications, as well as regulatory scrutiny over biosimilar entry, could impact market dynamics.

---

References

[1] MarketsandMarkets, "GnRH Agonists Market by Product, Application, Region - Global Forecast to 2027," 2022.